digital currency forecast searches

Goldman Sachs: I don't agree that gold can't reach $3,000 under a strong dollar. Goldman Sachs said that we don't agree with the view that the price of gold can't rise to $3,000 per ounce by the end of 2025 when the dollar remains strong for a long time. We predict that gold will reach $3,000 per ounce by the end of 2025, and the reduction of interest rate cuts by the Federal Reserve (rather than the strengthening of the US dollar) is the downside risk of this prediction. Huadian energy: The subordinate power plants and holding companies received government subsidies of 22.33 million yuan. huadian energy announced that the subordinate power plants and holding companies of the company received government subsidies related to income of 22.33 million yuan on December 9, 2024. Among them, Harbin No.3 Power Plant of huadian energy Co., Ltd. received a government subsidy of 10.87 million yuan, and Harbin Thermal Power Co., Ltd. received a government subsidy of 11.46 million yuan. In accordance with the relevant provisions of Accounting Standards for Business Enterprises No.16-Government Subsidies, the company included this subsidy in the current profit and loss, and it is estimated that the total profit of the company in 2024 will be increased by 8.39 million yuan.

Analyst: There may be a RRR cut of 50 basis points to 100 basis points next year. Tan Yiming, chief fixed income analyst of Minsheng Securities, said that there may be a RRR cut of 50 basis points to 100 basis points next year, considering the supply pressure of government bonds, the restoration of credit supply and the provision of long-term stable low-cost funds for financial institutions.South Korean Finance Minister and US Treasury Secretary Yellen confirmed that they will work closely together.South Korean Finance Minister and US Treasury Secretary Yellen confirmed that they will work closely together.

Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Market information: Honda will terminate its autonomous driving partnership with General Motors.Japanese Reuters's short-term non-manufacturing boom judgment index in December is 30, with the previous value of 19; Reuters's short-term judgment index of manufacturing prosperity in December was -1, with the previous value of 5.